Ann: Viraleze shows antiviral efficacy in COVID-19 patients, page-73

How do you know the trial failed for under 45’s? It may appear simple but as a reminder for the rest of us,

• ViralezeTM achieved a statistically significant reduction in SARS-CoV-2 viral load, the primary endpoint of the study, in the cohort of participants aged 45 and over (N=118, p=0.017).

• ViralezeTM reduced viral load in the full study population including all patient age groups (N=197), although the difference vs placebo was not statistically significant.

The p value for 45 years and over was 0.017.
Statistical significance is generally recognised as 0.05 or lower.
So, did the p value shoot up to 0.051 for the age group 44 and above? I don’t think so.
How about 43 and above? Or 42? 41?
We don’t know, so perhaps viraleze is good for 40+. Or perhaps 35+. Perhaps even 30+!
We do know it is not approved for under 18’s
At some point the p value reached 0.051 but it could have been when N =196. Again we don’t know. (Well, I don’t know!)
For whatever reason, the company has identified 45+ and that still needs to be explained and charted.